Contra-indicated in patients with a history of angioedema with or without previous ACE inhibitor treatment.
Not available in the USA.
- Trade Names: Inhibase (Roche); Vascace (Roche)
- Indications: Hypertension, chronic heart failure
- Class: Angiotensin-converting enzyme (ACE) inhibitor, Antihypertensive, Renin-angiotensin-aldosterone system (RAAS) inhibitor, Vasodilator
- Half-life: 9 hours
- Clinically important, potentially hazardous interactions with:
Alcohol, Aldesleukin, Allopurinol, Alpha blockers, Alprostadil, Angiotensin II receptor antagonists, Antacids, Antidiabetics, Antipsychotics, Anxiolytics and hypnotics, Aspirin, Baclofen, Beta blockers, Calcium channel blockers, Clonidine, Corticosteroids, Cyclosporine, Diazoxide, Diuretics, Estrogens, General anesthetics, Gold & Gold Compounds, Heparins, Hydralazine, Insulin, Levodopa, Lithium, MAO inhibitors, Metformin, Methyldopa, Minoxidil, Moxisylyte, Nitrates, Nitroprusside, NSAIDs, Potassium salts, Sulfonylureas, Sympathomimetics, Tizanidine, Trimethoprim
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 10/28/2026
